IGI Logo

Investment Rationale

* Turnaround in Financial Performance: Wockhardt has undergone a significant transformation in the past few years, shifting from a debtridden, compliance-hit generic drugmaker to a more focused, innovation-led pharmaceutical company. Post the divestment of its domestic formulations business to Dr. Reddy’s, the company deployed proceeds to deleverage the balance sheet and fund R&D. The company has revenues remained broadly stable, hovering between Rs 2,800 Cr and Rs 3,000 Cr annually, reflecting its shift from U.S. generics toward niche therapies and speciality products. After posting heavy net losses exceeding Rs 600 Cr in FY23—driven by regulatory challenges, high U.S. operating costs, and legal settlements—Wockhardt managed to narrow its losses substantially to just Rs 47 Cr in FY25. This turnaround was supported by cost rationalisation, the closure of the loss-making Morton Grove facility in the U.S.

* Upcoming Opportunities: Wockhardt has several new opportunities ahead. It recently launched Miqnaf (nafithromycin) in India to treat pneumonia, a big step as antibiotic resistance grows worldwide, with the global pneumonia antibiotic market estimated at over $3–4 Bn annually. Miqnaf also earned Breakthrough Medicinal Product status in Saudi Arabia, speeding up its potential entry into the Middle East market. Beyond Miqnaf, it has other innovative antibiotics like Zaynich (WCK-5222) in the pipeline, targeting infections with an estimated $9 Bn global market potential. The company is also branching into medical devices and diabetes care with products like the mypen 2 insulin device, tapping into a diabetes device market worth over $15 Bn globally. These moves could improve margins, open new revenue streams, and help Wockhardt return to profitability.

* Debt Reduction: In FY24 and FY25, Wockhardt significantly improved its financial footing by raising ~Rs 1,600 Cr through a Qualified Institutional Placement (QIP), following an earlier Rs 748 Cr rights issue. As a result, the company’s net debt stood at Rs 64 Cr in FY25 (ex Promoter debt), down sharply from over Rs 975 Cr two years ago. This reduction has lowered interest costs, helping narrow the FY25 net loss to Rs 47 Cr, a marked improvement from a Rs 463 Cr loss in FY24. With reduced leverage and healthier cash flows, Wockhardt now has greater flexibility to fund R&D for its new antibiotic pipeline and invest in global expansion. A leaner balance sheet and disciplined capital allocation put the company in a stronger position to monetise upcoming launches like Miqnaf and Zaynich, aiming to drive growth in both domestic and international markets

Valuation & Analyst recommendation:

* Wockhardt Ltd. is poised to benefit from its strategic focus on complex generics, biosimilars, and novel antibiotics. Management remains optimistic about improving operational performance, supported by new product launches and recovery in key markets like the US and Europe. Recent deleveraging efforts and cost rationalisation have strengthened the balance sheet, enhancing financial flexibility for future growth. The company’s differentiated pipeline, including breakthrough antibiotics like Miqnaf & Zaynich, positions it well in niche, high-value segments. We recommend a BUY rating on the stock, with a target price of Rs 1,870/share reflecting 10% upside potential from the CMP.

For More Axis Securities Disclaimer https://simplehai.axisdirect.in/disclaimer-home

SEBI Registration number is INZ000161633